G

GoodRx Holdings, Inc. (GDRX)

NMS – Real vaqt narxi. Valyuta: USD

2.69

-0.15 (-5.28%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

G

GoodRx Holdings, Inc. (GDRX)

NMS – Real vaqt narxi. Valyuta: USD

2.69

-0.15 (-5.28%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

07.05.2026

Big Pharma Runs Its Checkout Counter Through GoodRx

Out-of-pocket drug costs are rising for millions of Americans. Coverage gaps are widening.

07.05.2026

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.

07.05.2026

GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

06.05.2026

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.

06.05.2026

GoodRx Reports First Quarter 2026 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.

29.04.2026

Hims & Hers Expands Digital-First Access to Personalized Healthcare

HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

GoodRx Reports First Quarter 2026 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.

15.04.2026

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an.

09.04.2026

GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide.

11.03.2026

GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cas.

Search stocks

GoodRx Holdings, Inc. (GDRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

GoodRx Holdings, Inc. (GDRX)

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

Big Pharma Runs Its Checkout Counter Through GoodRx

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

GoodRx Reports First Quarter 2026 Results

Hims & Hers Expands Digital-First Access to Personalized Healthcare

Videolar

No Data

Press-relizlar

GoodRx Reports First Quarter 2026 Results

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications